Linkage of mother–baby pairs in the German Pharmacoepidemiological Research Database
- 11 November 2010
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 20 (3), 258-264
- https://doi.org/10.1002/pds.2038
Abstract
Purpose Administrative healthcare databases are increasingly being used to investigate potential drug risks in pregnancy. Our study aimed to develop an algorithm for linkage of mother–baby pairs (MBPs) in the German Pharmacoepidemiological Research Database (GePaRD) as a prerequisite for such studies. Methods GePaRD contains sociodemographic data, drug dispensations, ambulatory, and hospital information on more than 14 million insurants from four German statutory health insurances (SHIs) covering all regions in Germany. Linkage was based on co-insurance information of the newborn with the potential mother (direct linkage) or of both potential mother and newborn with the potential father (indirect linkage). Linkage is not possible if the baby is co-insured with the father and the mother is self-insured. Further information on birth or childbed was used to validate the potential mother as true mother in MBP. Descriptive comparisons between linked and unlinked mothers were conducted. Results Of 323 993 newborns identified between 2004 and 2006, 250 355 (77.3%) could be linked in MBP. Of those, 189 702 (75.8%) MBP were based on direct linkage. Mean age was similar in linked (31.1 years, standard deviation (SD = 5.4) and unlinked (31.8 years, SD = 5.5) mothers as was the proportion of caesarean sections in both groups (28.9% vs. 29.3%). Conclusions The developed algorithm permits linkage of a great number of newborns with their mothers and creates a potential data source for investigation of drug risks in pregnancy. Further validation studies are needed also including information on pregnancies not resulting in live births. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 24 references indexed in Scilit:
- Prescriptions filled during pregnancy for drugs with the potential of fetal harmBJOG: An International Journal of Obstetrics and Gynaecology, 2009
- Antidepressant medication use and risk of persistent pulmonary hypertension of the newbornPharmacoepidemiology and Drug Safety, 2009
- Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitationsPharmacoepidemiology and Drug Safety, 2008
- Data Resources for Investigating Drug Exposure during Pregnancy and Associated OutcomesDrug Safety, 2008
- Positive predictive value of computerized records for major congenital malformationsPharmacoepidemiology and Drug Safety, 2007
- Major Congenital Malformations after First-Trimester Exposure to ACE InhibitorsThe New England Journal of Medicine, 2006
- Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund populationPharmacoepidemiology and Drug Safety, 2006
- Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the NewbornThe New England Journal of Medicine, 2006
- Post-marketing surveillance system for drugs in pregnancy—15 years experience of ENTISReproductive Toxicology, 2005
- Birth Outcomes in Pregnant Women Taking FluoxetineThe New England Journal of Medicine, 1996